MALCOLM BRENNER to Cytomegalovirus
This is a "connection" page, showing publications MALCOLM BRENNER has written about Cytomegalovirus.
Connection Strength
0.719
-
Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood. 1992 Jun 01; 79(11):3059-66.
Score: 0.090
-
IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):81-7.
Score: 0.082
-
CMV-induced augmentation of GVL effect may be mediated by cytokines. Bone Marrow Transplant. 1991 Jan; 7(1):69.
Score: 0.082
-
Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53.
Score: 0.080
-
Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1987 Apr 04; 1(8536):774-6.
Score: 0.063
-
Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
Score: 0.052
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.032
-
Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seropositive donors. J Med Virol. 1993 Oct; 41(2):150-8.
Score: 0.025
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.025
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.024
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.024
-
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
Score: 0.023
-
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
Score: 0.023
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.019
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.018
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.017
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.015
-
Production of anti-cytomegalovirus antibody following T-cell depleted bone marrow transplant. Br J Haematol. 1986 Aug; 63(4):659-64.
Score: 0.015
-
Transfection and gene expression in normal and malignant primary B lymphocytes. J Immunol Methods. 1990 Oct 04; 133(1):77-85.
Score: 0.005
-
T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol. 1986 Mar; 63(3):577-86.
Score: 0.004